Toll Free: 1-888-928-9744

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 126 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2016', provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Bipolar Disorder (Manic Depression) therapeutics and enlists all their major and minor projects
- The report assesses Bipolar Disorder (Manic Depression) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Bipolar Disorder (Manic Depression) Overview 10 Therapeutics Development 11 Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11 Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12 Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13 Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15 Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Bipolar Disorder (Manic Depression) - Products under Development by Companies 19 Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 21 Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 22 Aequus Pharmaceuticals Inc. 22 Amorsa Therapeutics Inc. 23 AstraZeneca Plc 24 Biogen, Inc. 25 D-Pharm Ltd. 26 Delpor, Inc. 27 Intas Pharmaceuticals Ltd. 28 Intra-Cellular Therapies, Inc. 29 Johnson & Johnson 30 KemPharm, Inc. 31 Mapi Pharma Ltd. 32 Navya Biologicals Pvt Ltd 33 Neurocrine Biosciences, Inc. 34 Omeros Corporation 35 Otsuka Holdings Co., Ltd. 36 Pfizer Inc. 37 Reviva Pharmaceuticals Inc. 38 SK Biopharmaceuticals Co., Ltd. 39 Sumitomo Dainippon Pharma Co., Ltd. 40 Zogenix, Inc. 41 Zysis Limited 42 Bipolar Disorder (Manic Depression) - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (cycloserine + lurasidone hydrochloride) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 aripiprazole - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 aripiprazole CR - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 aripiprazole ER - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CNV-1061436 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 DP-VPA - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Drug for Bipolar Disorder - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 ebselen - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Endoxifen - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ITI-007 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 JNJ-18038683 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 KP-303 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 lurasidone hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NAV-003 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 paliperidone palmitate - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PGW-5 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 quetiapine fumarate ER - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 risperidone - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 risperidone - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 risperidone - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 RP-5063 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SKL-PSY - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecule for Bipolar Disorder - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule for Cancer and Neurodegenerative Disease - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules for Bipolar Depression - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 YKP-3089 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 ziprasidone mesylate - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Bipolar Disorder (Manic Depression) - Recent Pipeline Updates 95 Bipolar Disorder (Manic Depression) - Dormant Projects 112 Bipolar Disorder (Manic Depression) - Discontinued Products 115 Bipolar Disorder (Manic Depression) - Product Development Milestones 116 Featured News & Press Releases 116 Apr 26, 2016: FDA Issues Complete Response Letter For Digital Medicine New Drug Application 116 Feb 25, 2016: Intra-Cellular Therapies Provides Product Update 116 Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch 118 Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression 118 Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder 119 Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch 121 Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 121 Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder 122 May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 122 Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry 123 Appendix 125 Methodology 125 Coverage 125 Secondary Research 125 Primary Research 125 Expert Panel Validation 125 Contact Us 125 Disclaimer 126
List of Tables
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2016 11 Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 22 Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H1 2016 23 Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H1 2016 24 Bipolar Disorder (Manic Depression) - Pipeline by Biogen, Inc., H1 2016 25 Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H1 2016 26 Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H1 2016 27 Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 28 Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 29 Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H1 2016 30 Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H1 2016 31 Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H1 2016 32 Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H1 2016 33 Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences, Inc., H1 2016 34 Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H1 2016 35 Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 36 Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H1 2016 37 Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 38 Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 39 Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 40 Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H1 2016 41 Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Assessment by Combination Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H1 2016 95 Bipolar Disorder (Manic Depression) - Dormant Projects, H1 2016 112 Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H1 2016 113 Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H1 2016 114 Bipolar Disorder (Manic Depression) - Discontinued Products, H1 2016 115


List of Figures
Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2016 11 Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 43 Number of Products by Top 10 Targets, H1 2016 45 Number of Products by Stage and Top 10 Targets, H1 2016 45 Number of Products by Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47 Number of Products by Routes of Administration, H1 2016 49 Number of Products by Stage and Routes of Administration, H1 2016 49 Number of Products by Molecule Types, H1 2016 51 Number of Products by Stage and Top 10 Molecule Types, H1 2016 51

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify